Medications for menopause-associated vasomotor and genitourinary symptoms

Personalized education for health care professionals in 30-60 minutes either in-person or via web conferencing (e.g., Zoom) at a time and location that is convenient for you. This activity has been certified by the College of Family Physicians of Canada and the British Columbia Chapter for up to 1.0 Mainpro+ Certified Activity credits.

Learning objective

During each academic detailing session, participants will have the opportunity to apply current evidence and practical drug information to support shared decision making including:

• The most commonly prescribed estrogen and progestogen products (oral, transdermal, vaginal) prescribed in B.C. for vasomotor and genitourinary symptoms
• The first non-hormonal medication approved by Health Canada in 2024 for vasomotor symptoms: fezolinetant
• Transdermal testosterone for hypoactive sexual desire disorder

After the PAD session, participants will be able to thoughtfully discuss, prescribe, monitor and manage medications used for menopause-associated vasomotor and genitourinary symptoms.

Availability

When: Until May 20, 2026
Where: In-person at your place of work or virtual academic detailing
How: Contact your local PAD pharmacist directly or e-mail PAD@gov.bc.ca

Resources

• Handout - PAD Medications for menopause (PDF, 538KB)
• Drug table - PAD Medications for menopause (PDF, 108KB)
• References - PAD Medications for menopause (PDF, 170KB)

For more information about the PAD service, visit About PAD service.